21
Participants
Start Date
April 30, 2014
Primary Completion Date
March 31, 2017
Study Completion Date
March 31, 2017
Exenatide
Single subcutaneous injection (10 mcg)
Saxagliptin
Single dose orally (5 mg)
Exenatide extended-release (ER)
Subcutaneous injection (2mg) weekly for 6 weeks
Placebo
Placebo tablets and Placebo (normal saline) injections
The University of Texas Health Science Center at Houston, Houston
The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston
OTHER
The University of Texas Health Science Center, Houston
OTHER